Phase 4 N=457 Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II
Cerebral Infarction · Atherosclerosis
Primary: Number of Participants With Progression of Symptomatic Intracranial Stenosis — 20; 32 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=113,035 Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization
Stroke
Primary: All-cause Mortality During Hospitalization of Acute Ischemic Stroke (AIS) Patients — 2.6; 0.8 Percentage of participants
N/A N=12,551 1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients
Stroke
Primary: All-cause Mortality at 1 Year (Percentage of Patients With Modified Rankin Scale (mRS) Score =6) — 11.1; 12.2 Percentage of Participants — p=0.183
N/A N=52 Surgical Indirect Revascularization For Symptomatic Intracranial Arterial Stenosis
Intracranial Arterial Stenosis · Intracranial Atherosclerosis · Ischemic Stroke
Primary: Stroke or Death in the Territory of Qualifying Artery — 5 Participants — p=0.08
Phase 2 N=31 NeuroCognition After Carotid Recanalization
Cognition Disorder · Stroke · Occlusion Carotid
Primary: Change in Montreal Cognitive Assessment (MoCA) Score — 0.56; 1.38; -0.75; 0.50 score on a scale
N/A N=1,560 Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients
Stroke
Primary: Percentage of Patients With Favourable Outcome (Modified Rankin Scale (mRS) 0-1) at 1 Year — 27.7; 23.8 Percentage of Participants — p=<0.001
Phase 1 N=24 A Phase Ib/II in Patients With Acute Ischemic Stroke
Ischemic Stroke
Primary: Maximum Tolerated Dose (MTD) of DDFPe Evaluated by Number of Dose Limiting Toxicities — 0; 0; 0; 0 Dose Limiting Toxicities
N/A N=2 Pilot Study of Pre-Ischemic Conditioning for Intracranial Atherosclerosis
Intracranial Atherosclerosis
Primary: Percent Change in Cerebral Blood Flow (CBF) — 0; 25 percentage increase in CBF
Phase 2 N=65 Argatroban Stroke Treatment - A Pilot Safety Study
Ischemic Stroke
Primary: Symptomatic and Radiographic Intracerebral Hemorrhage — 6.2 percentage of patients
Phase 2 N=88 A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects
Acute Ischemic Stroke
Primary: The Proportion of Subjects With Adverse Events (AEs), Judged to be Probably or Definitely Related to the Investigational Product (IP), Within 90 Days After the First IP…
Phase 4 N=401 Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke
Cerebral Infarction
Primary: the Rate of Patients With a Modified Rankin Scale Score of 0-1 — 109; 98; 46; 39 participants
N/A N=12,012 Vascular Ultrasound Screening in Patients With Ischemic Cerebrovascular Disease: a Multi-center Registry Study
Stroke
Primary: Evidence of Carotid Artery or Intracranial Artery Atherosclerosis Confirmed by Vascular Ultrasonography — 96; 1063; 826; 241 artery numbers
Phase 2 N=18 Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)
Ischemic Stroke
Primary: Symptomatic Intracerebral Hemorrhage (ICH) — 1; 1 participants
Phase 3 N=451 Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis
Ischemic Stroke
Primary: Any Stroke or Death Within 30 Days of Enrollment or Any Revascularization Procedure OR an Ischemic Stroke in the Territory of the Symptomatic Intracranial Artery Beyond…
N/A N=80 Deep Learning Enabled Endovascular Stroke Therapy Screening in Community Hospitals
Acute Ischemic Stroke (AIS)
Primary: Time From Emergency Room Arrival to Initiation of Endovascular Stroke Therapy ("Door-to-groin" Time) — 100; 88 minutes
N/A N=400 Investigation of Clot in Ischemic Stroke and Hematoma Evacuation
Ischemic Stroke · Intracranial Hematoma
Primary: Clot Specimen Histology — 373; 12 Count of specimen
N/A N=16 American Heart Association- Stroke/Hypoxia Study
Stroke
Primary: Number of Participants With Adverse Events — 1; 11; 2; 10 Participants
N/A N=984 Systematic Evaluation of Patients Treated With Stroke Devices for Acute Ischemic Stroke (STRATIS) Registry
Ischemic Stroke
Primary: Number of Participants Assessed for Revascularization With mTICI Grades 2b-3 — 724 Participants
N/A N=82 Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke (VERiTAS)
Vertebrobasilar Insufficiency · Ischemic Attack, Transient · Cerebrovascular Disorder
Primary: Fatal and Nonfatal Ischemic Stroke in the Vertebrobasilar Territory — 72 Participants
Phase 2 N=6 A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)
Arterial Ischemic Stroke
Primary: Changes in Volume of Infarct — 9.97; 4.06 mL — p=0.0313
N/A N=4,071 China Antihypertensive Trial in Acute Ischemic Stroke
Ischemic Stroke
Primary: A Combination of Death Within 14 Days After Randomization and Major Disability at 14 Days or at Hospital Discharge if Earlier Than 14 Days. — 681; 683 participants
N/A N=82 An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis
Intracranial Atherosclerosis
Primary: Successful Wingspan™ Stent Implantation (Access to the Lesion With the Stent, Accurate Deployment of the Stent Across the Target Lesion) — 78 patients w stent implanted
Phase 3 N=458 Tenecteplase in Stroke Patients Between 4.5 and 24 Hours
THROMBOLYSIS
Primary: Ordinal Modified Rankin Scale (mRS) Score at Day 90 — 35; 31; 38; 30 Count of participants
Phase 2 N=40 Safety of Intravenous Thrombolysis for Wake-up Stroke
Ischemic Stroke
Primary: Frequency of Symptomatic Hemorrhagic Transformation Safety of iv Rt-PA in Wake up Stroke Patients — 0 cases.
N/A N=1,196 Coordinated, Collaborative, Comprehensive, Family-based, Integrated, Technology-enabled Stroke Care
Stroke · Stroke, Ischemic · Stroke, Acute
Primary: Stroke Impact Scale (SIS) at 12-months Post-discharge — 80.42; 83.85 Score
Phase 4 N=58 Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke （Japan Alteplase Clinical Trial Ⅱ：J-ACT Ⅱ）
Stroke
Primary: Number of Patients With Valid Recanalization Assessed by Magnetic Resonance Angiography (MRA) — 30; 40 participants
Phase 2 N=126 Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke
Ischemic Stroke · Stroke · Brain Infarction
Primary: Symptomatic Intracranial Hemorrhage (sICH) Within 36 Hours of Treatment Onset — 3; 2; 22; 99 participants — p=0.053
Phase 2 N=125 Study to Assess the Safety and Effectiveness of the Penumbra System
Stroke
Primary: Percentage of Participants With Revascularization of the Occluded Target Vessel — 81.2 Percentage of Participants
Phase 1 N=57 The Capillary Index Score Trial
Acute Stroke · Brain Ischemia · Ischemic Stroke
Primary: Modified Rankin Score (mRS) Between Favorable CIS Group Versus Poor CIS Group. — 22; 1; 23; 10 Participants
Phase 3 N=514 Multi-arm Optimization of Stroke Thrombolysis
Acute Ischemic Stroke
Primary: 90-day Utility Weighted Modified Rankin Scores (UW-mRS) — 5.2; 6.3; 6.8 score on a scale — p=0.002